TVTX: Wedbush Raises Target
Wedbush maintains Outperform on Travere Therapeutics and raises price target to $61
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61
Wedbush maintains Outperform on Travere Therapeutics and raises price target to $61
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61